Antibodies have been fastest-growing and powerful biomedical research tools and potential drugs for a wide range of conditions from cancers to autoimmune diseases.
Although antibody technology has developed for several decades, there are still challenges in antibody generation with speed and quality. Antibodies having high specificity and high affinity against native protein are still in high demand.
Our antibody production adopts a different strategy which can:
TME platform has successfully generated many monoclonal antibodies that have been validated for diagnostic tools or therapeutic drugs.